Top

Published in:

01-07-2012 | Media release

The EMA has recommended restrictions on the use of the muscle relaxant tolperisone following a review of its risk-benefit profile.

Published in: Reactions Weekly | Issue 1/2012

Excerpt

The EMA has recommended restrictions on the use of the muscle relaxant tolperisone following a review of its risk-benefit profile. The review was conducted by the CHMP following concerns from Germany over post-marketing reports of hypersensitivity reactions and insufficient evidence of efficacy in some indications. The CHMP concluded that tolperisone demonstrated a favourable risk-benefit profile only in adult patients with post-stroke spasticity, and only when given orally. …

EMA.Medicines Agency recommends restricting use of tolperisone medicines. Media Release: 22 Jun 2012. Available from: URL: http://www.ema.europa.eu

Title: The EMA has recommended restrictions on the use of the muscle relaxant tolperisone following a review of its risk-benefit profile.
Publication date: 01-07-2012
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2012
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-201214090-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The EMA has recommended restrictions on the use of the muscle relaxant tolperisone following a review of its risk-benefit profile.

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Olanzapine/risperidone/zuclopenthixol

Hydromorphone/oxycodone/zolpidem

Diclofenac/metformin

Paracetamol overdose

Zoledronic acid

Ciclosporin